Trimetrexate

CHEMBL119 Phase 4 Aprobado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

369.4 g/mol

LogP

2.5

Phase

4

Trimetrexate is a lipophilic antifolate that inhibits dihydrofolate reductase (DHFR), blocking tetrahydrofolate synthesis required for DNA replication, thereby exerting cytotoxic effects on rapidly dividing cells. It was used as an alternative treatment for Pneumocystis jirovecii pneumonia in immunocompromised patients and investigated as an antineoplastic agent in colorectal cancer and leukemia. It requires leucovorin rescue to protect normal host cells.

Peso molecular

369,4000 g/mol

LogP

2,50

TPSA

118,00 Å²

Regla de cinco de Lipinski

Cumple

Áreas terapéuticas

Pancreatic Cancer Lymphoma Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estructura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC

InChI

InChI=1S/C19H23N5O3/c1-10-11(5-6-13-16(10)18(20)24-19(21)23-13)9-22-12-7-14(25-2)17(27-4)15(8-12)26-3/h5-8,22H,9H2,1-4H3,(H4,20,21,23,24)

Molecular Formula

C19H23N5O3

HBD / HBA

3 / 8

Enlaces Rotables

6

Átomos Pesados

27

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

Trimetrexate is a lipophilic antifolate that inhibits dihydrofolate reductase (DHFR), blocking tetrahydrofolate synthesis required for DNA replication, thereby exerting cytotoxic effects on rapidly dividing cells. It was used as an alternative treatment for Pneumocystis jirovecii pneumonia in immunocompromised patients and investigated as an antineoplastic agent in colorectal cancer and leukemia. It requires leucovorin rescue to protect normal host cells.

Yes, Trimetrexate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL119. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5583. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

¿Busca información accesible para el paciente?

Trimetrexate en PillFYI

Estructura

Datos Rápidos

Fórmula: C19H23N5O3

Enlaces externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.